XRP News Today: SWIFT Talks, Spot ETF Bets Fuel XRP Adoption Speculation
Ripple eyes favorable terms in cross-appeal talks. A SWIFT deal and spot ETF approval may drive XRP past key resistance and ...
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...
KIWA Radio2d
Sheldon City Council Talks About Ambulance Service With County EMA Director
The Sheldon City Council met in regular session on Wednesday, March 19th, 2025 in the City Hall Council Chambers at the Sheldon Community Services Center, downtown. By […] ...
Novartis2d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
Science Daily2d
New data on Mpox vaccine effectiveness
A study has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer ...
Beware of unproven cancer treatments advertised online, EU medicine regulators say
The warning comes amid reports that unregulated therapies are being offered directly to patients, potentially illegally. View ...
Single vaccine dose shows 84% effectiveness against mpox, but insufficient for HIV patients
Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against mpox with 84% ...
EurekAlert!4d
Charité study yields new data on Mpox vaccine effectiveness
Universitätsmedizin Berlin has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% ...
The American Journal of Managed Care9d
Uniform Global Standards, Processes Could Accelerate CGT Approvals, Access
The study found that just 20% of trials submitted to both the FDA and European Medicines Agency had matching evidence.
Business Wire11d
Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today an ...